Various modifications in or near SOST can cause abnormal bone mineral density such as Sclerosteosis and Van Buchem disease (Holdsworth et al., 2019). Sclerostin transgenic mice exhibit osteopenia (Winkler et al., 2003). Regulate differentiation and mineralization of osteogenic lineage cell via a MEPE-ASARM dependent mechanism (Atkins et al., 2011). Sclerostin inhibition could reactive quiescent bone lining cells (Kim S.W. et al., 2017). The gene discussed is SOST; the disease is hyperostosis corticalis generalisata.